The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001059358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
12/08/2026
Date registered
Help: Date registered
27/08/2026
Date last updated
Help: Date last updated
27/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
27/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Bioactive Dietary Pattern for Blood Pressure (BioBP) for People with Type 2 Diabetes and Pre-diabetes; A Randomised Pilot Cross-Over Feeding Study
Scientific title
Bioactive Dietary Pattern for Blood Pressure (BioBP) for People with Type 2 Diabetes and Pre-diabetes; A Randomised Pilot Cross-Over Feeding Study in Adults
Additional trial identifiers [1] 318160 0
Nil
Universal Trial Number (UTN)
Trial acronym
BioBP
Related trial records

Health condition
Health condition(s) studied:
Type 2 Diabetes 343211 0
Hypertension 343212 0
Pre-diabetes 343213 0
Condition category
Condition code
Cardiovascular 339300 339300 0 0
Hypertension
Diet and Nutrition 339301 339301 0 0
Other diet and nutrition disorders
Metabolic and Endocrine 339302 339302 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Eight-week dietary intervention consisting of a 2-week run-in period (habitual/usual diet) followed by dietary pattern 1 for 2 weeks, 2-week washout period (habitual/usual diet), then lastly dietary pattern 2 for 2 weeks in a randomised order. The entirety of the diet (i.e., 3 main meals and snacks per day) will be provided to participants during dietary phase 1 and 2. Participants will supply their own meals and foods during the run-in and washout periods. Participants will be instructed to return to and maintain their habitual diet in the run-in and washout period, with adherence to this assessed with 2x 24 hour recalls at each timepoint including washout and run-in periods. The two dietary phases will consist of a “healthy Australian dietary pattern + bioactive foods” (HAD+) and a “healthy Australian dietary pattern” (HAD) that will be matched to participant’s usual caloric intake as assessed during the run-in period. Both the HAD+ and HAD will be matched for their sodium and potassium intakes to ensure this does not confound blood pressure (BP) responses. Energy, sodium and potassium for each diet was created using Foodworks. Dietary intake and compliance will be checked using 24 hour food recalls and spot urine samples.

The HAD+ will have foods from the 5 core food groups from the current Australian Dietary Guidelines for adults with the addition of high bioactive foods that have been associated with reducing BP. The diet aims to meet the Acceptable Macronutrient Distribution Ranges (AMDR) e.g., 15-25% energy from protein, 45-65% energy from carbohydrates, 20-35% energy from fat; less than or equal to 10% energy from saturated fat and less than or equal to 1% energy from trans fat. Fibre intake may exceed the 25-30g/day recommendation due to the focus on soluble fibres. Sodium/potassium ratio will be matched with the HAD+ and the HAD plan. Nitrate rich vegetables are also included in this diet. The key foods in the HAD+ diet will include oats, beetroot, leafy green vegetables, flaxseeds, citrus fruit, and mixed nuts.

All meals and snacks are provided to participants for the duration of both 2-week diet intervention phases. This includes pre-prepared main meals (e.g., ready made fresh meals or frozen meals), fresh produce, cereals and snacks. Study investigators calorie-match the foods (to the participants baseline usual calorie intake) to be provided which are placed as a grocery order by the study investigators during the appointment with the participants at the preceding phase. Participants collect the pre-ordered and pre-paid grocery items at their nearest allocated supermarket chain or via home delivery. The dietary intervention has been designed by and will be monitored by study coordinators who are also accredited practising dietitians. Participants are instructed to avoid consuming non-study foods, with usual beverage intake permitted except for discretionary choice beverages.
Adherence to protocol will be examined during the 2-week run-in & washout periods prior to the feeding interventions and will be reassessed throughout the feeding intervention periods.
Participants who do not meet adherence guidelines during the run-in period will be withdrawn from the study prior to randomisation. Adherence measures during the run-in period will include:
• Collection of two 24-hour recalls
• Record keeping of habitual consumption of tea, coffee, and alcohol (using Easy Diet Diary app or written food record as per participant preference)
• Record keeping of any food consumed out of the home e.g., takeaway, restaurant / café foods (using Easy Diet Diary app or written food record)
• Completion of one AES®-Heart survey
• Collection of each biospecimen: urine, blood and faecal samples
• Completion of one 24-hour ambulatory BP monitoring

After completion of each dietary intervention phase, participants undergo a 2-week washout period where they return to their usual food habits, eating their own food (i.e., no food is supplied during the washout period).

Upon enrolment, consent participants commence a 2-week run-in period prior to their first diet allocation. During the run-in period where they continue to consume their habitual diet (note, food is not supplied by study investigators for the run-in period). The run-in period includes collection of baseline data.
Intervention code [1] 335050 0
Treatment: Other
Description of the comparator or control
The Healthy Australian Diet (HAD) will provide foods to adequately meet the recommended servings of the 5 core food groups according to the current Australian Dietary Guidelines for adults e.g., 5.5 servings of grains/cereals; 5 servings of vegetables/legumes/beans; 2 servings of fruit; 3 servings of milk/yoghurt/cheese/alternatives and 2.5 servings of lean meats/alternatives. The diet aims to meet the Acceptable Macronutrient Distribution Ranges (AMDR) e.g., 15-25% energy from protein, 45-65% energy from carbohydrates, 20-35% energy from fat; less than or equal to 10% energy from saturated fat and less than or equal to 1% energy from trans fat. Some emphasis will be given to specific nutrient targets such as fibre, free sugars, and sodium. Participants will be instructed to avoid consuming non-study foods, with usual beverage intake permitted and discretionary choice beverages encouraged. Participants undergo the identical process of food provision as in the intervention phase i.e., all foods/meals provided for the 2-week duration of the comparator feeding phase with the diet calorie-matched for each participant by the study coordinators (accredited practising dietitians). The same adherence protocol checklist and items employed during the intervention phase are also employed during this diet phase.
Control group
Active

Outcomes
Primary outcome [1] 346524 0
This pilot study has co-primary feasibility and efficacy outcomes. Feasibility outcomes include recruitment rate, participant retention, dietary adherence, and ambulatory blood pressure monitoring (ABPM) data quality, which will be summarised descriptively as a composite outcome.
Timepoint [1] 346524 0
The timepoints at which each aspect of the feasibility outcome will be assessed are: a) Recruitment: at the end of the recruitment period. b) Retention: at the end of the trial period. c) Adherence: at the end of both intervention periods. d) Data completeness: at the end of both intervention periods. e) Acceptability: at the end of both intervention periods.
Primary outcome [2] 346525 0
The co-primary efficacy outcome is the within-period change in mean 24-hour ambulatory systolic blood pressure defined as the difference between baseline and end-of-period measurements for each 2-week dietary intervention.
Timepoint [2] 346525 0
Baseline (end of run-in phase), Week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [1] 466229 0
Arterial Stiffness.
Timepoint [1] 466229 0
Baseline (end of run-in phase), week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [2] 466231 0
Urinary metabolites (exploratory outcome).
Timepoint [2] 466231 0
Baseline (end of run-in phase), week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [3] 466232 0
Plasma metabolites (exploratory outcome).
Timepoint [3] 466232 0
Baseline (end of run-in phase), week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [4] 466233 0
Plasma short-chain fatty acids.
Timepoint [4] 466233 0
Baseline (end of run-in phase), week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [5] 466234 0
Fasting blood glucose.
Timepoint [5] 466234 0
Baseline (end of run-in phase), week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [6] 466236 0
Faecal flora.
Timepoint [6] 466236 0
Baseline (end of run-in phase), week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [7] 466237 0
Genetic risk score.
Timepoint [7] 466237 0
Baseline (end of run-in phase), Week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [8] 466238 0
Quantitative dietary intake.
Timepoint [8] 466238 0
Weekly. Baseline (Week 1 & Week 2 - Run-in phase), Week 3 & 4 (diet phase 1), Week 5&6 (end of washout) and Week 7 & 8 (end of diet phase 2).
Secondary outcome [9] 466239 0
Qualitative dietary intake.
Timepoint [9] 466239 0
Baseline (end of run-in phase).
Secondary outcome [10] 466240 0
Weight.
Timepoint [10] 466240 0
Baseline (end of run-in phase), week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [11] 466241 0
Height.
Timepoint [11] 466241 0
Baseline (end of run-in phase).
Secondary outcome [12] 466242 0
Body composition.
Timepoint [12] 466242 0
Baseline (end of run-in phase), week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [13] 466243 0
Waist circumference
Timepoint [13] 466243 0
Baseline (Week 2, end of run-in phase), Week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [14] 466244 0
Physical activity.
Timepoint [14] 466244 0
Baseline (end of run-in phase), week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [15] 466245 0
Skin carotenoids.
Timepoint [15] 466245 0
Baseline (Week 2, end of run-in phase), Week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [16] 466246 0
Food security.
Timepoint [16] 466246 0
Baseline (end of run-in phase).
Secondary outcome [17] 466247 0
Quality of life
Timepoint [17] 466247 0
Baseline (end of run-in phase), week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [18] 466248 0
Perceived stress
Timepoint [18] 466248 0
Baseline (end of run-in phase), week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [19] 466720 0
Diastolic blood pressure.
Timepoint [19] 466720 0
Baseline (end of run-in phase), week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [20] 466721 0
Systolic blood pressure.
Timepoint [20] 466721 0
Baseline (end of run-in phase), week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [21] 466722 0
Urinary sodium.
Timepoint [21] 466722 0
Baseline (end of run-in phase), Week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [22] 466723 0
Urinary potassium.
Timepoint [22] 466723 0
Baseline (end of run-in phase), Week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [23] 466724 0
Urinary creatinine.
Timepoint [23] 466724 0
Baseline (end of run-in phase), Week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [24] 466729 0
Urinary sodium to potassium ratio.
Timepoint [24] 466729 0
Baseline (end of run-in phase), Week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [25] 466736 0
Fasting triglycerides.
Timepoint [25] 466736 0
Baseline (end of run-in phase), week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [26] 466737 0
Fasting Total cholesterol
Timepoint [26] 466737 0
Baseline (end of run-in phase), week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [27] 466738 0
Fasting LDL-cholesterol.
Timepoint [27] 466738 0
Baseline (end of run-in phase), week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).
Secondary outcome [28] 466739 0
Fasting HDL-cholesterol.
Timepoint [28] 466739 0
Baseline (end of run-in phase), week 4 (end diet phase 1), Week 6 (end of washout) and Week 8 (end of diet phase 2).

Eligibility
Key inclusion criteria
• Adults 18 years or older with high blood pressure and T2DM
• Living within 50km of Newcastle (postcode 2300)
• Hypertension diagnosis verified by doctor/healthcare professional or use of anti-hypertensive medications(1)
• Type 2 diabetes or pre-diabetes
o Type 2 diabetes diagnosis verified by NDSS number, doctor/healthcare professional, use of oral hypoglycaemic medications, insulin(2, 3) or verification of impaired fasting glucose greater than 7.0mmol/L if not medicated or HbA1c of greater than or equal to 6.5%(4)
o Pre-diabetes diagnosis verified by doctor/healthcare professional, HbA1c 6.0-6.4%, impaired fasting glucose (6.1-6.9mmol/L) or impaired glucose tolerance based on oral glucose tolerance test (fasting blood glucose less than 7.0mmol/L AND 2-hour blood glucose greater than or equal to 7.8 and less than 11.1mmol/L)(4)
• Willing to adhere to strict diet protocol for 8 weeks
• Willing to wear a 24-hour blood pressure cuff for 4 days throughout the 8-week study period
• Access to a smart phone or tablet with access to the internet
• In the Newcastle region for at least the entirety of the two feeding intervention periods
• Willing to come to the University of Newcastle for data collection appointments before and after each feeding phase
• Those who take vitamin and mineral supplements will be included if the trial if doses can be kept consistent throughout the 8-week trial period.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Any food allergies or intolerances
• Those receiving cancer treatment
• Those with stage 3b to stage 5 chronic kidney disease (estimated glomerular filtration rate less than 44mL/min)
• People who follow a specific diet (e.g. Vegan or vegetarians)
• Non-compliance during the 2-week run-in period
• Individuals who have lost or gained greater than or equal to 5% body weight in the past 2 months
• History of gastric ulcers, gastrointestinal disorders including severe digestive disorders such as irritable bowel syndrome
• On medications known to influence study outcomes e.g. antibiotics, probiotics or prebiotics, hormone therapy, anti-inflammatory medications, corticosteroids, medications affecting metabolism
• Have used antibiotics in the past 3 months
• Currently using GLP-1 agonists such as semaglutide (Ozempic), dulaglutide (Trulicity), liraglutide (Victoza); or tirzepatide (Mounjaro)
• On unstable medication regimen or have had blood pressure or diabetes medication changes (including dose) in the past 6 weeks.
• Currently participating in another research intervention trial involving dietary intervention and/or physical activity intervention
• Pregnant or breastfeeding

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Allocation to treatment periods will be based on computer-generated block randomisation method stratified by enrolment as an individual or couple.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
This is a proof-of-concept pilot study designed to assess feasibility, estimate effect sizes and variability, and generate preliminary metabolomic profiles to inform a future definitive trial. We will recruit 36 participants (approximately 30 completers assuming 15% dropout, or approximately 15 per sequence). This aligns with established pilot study methodology recommending 12-15 participants per sequence for adequate parameter estimation in crossover designs. No formal hypothesis testing power calculation was performed, as this pilot study is designed to assess feasibility and to estimate effect sizes to inform future trials.

Feasibility outcomes (recruitment rate, retention, adherence, and ABPM data quality) will be reported descriptively with 95% confidence intervals. The study will be considered feasible if retention is greater than or equal to 80%, adherence greater than or equal to 75%, and ABPM data quality greater than or equal to 80%. Reasons for dropout and non-adherence will be tabulated.
The co-primary efficacy outcome and all secondary blood pressure outcomes will be analysed using linear mixed-effects models appropriate for a 2-period randomised crossover design. Models will include dietary treatment (HAD+ vs HAD), period (period 1 vs period 2), and sequence (HAD then HAD+ vs HAD+ then HAD) as fixed effects, with participant included as a random effect to account for within-subject correlation. The treatment effect will be estimated as the average within-person difference in SBP change between dietary interventions, adjusted for period and sequence effects. Least-squares mean changes and 95% confidence intervals will be estimated for each treatment. Results will be reported as the mean treatment difference with corresponding confidence interval, a standardised paired effect size, and a two-sided p-value (a = 0.05), and will be interpreted cautiously given the pilot nature of the study and its primary focus on feasibility and effect size estimation.
Sensitivity analyses will assess robustness of findings to potential residual/carryover effects by including a treatment-by-period interaction and by repeating the primary analysis using Period 1 data only. Effect modification by diabetes status and baseline SBP tertiles will be explored using interaction terms if data allows. A complete-case analysis will be compared with the primary analysis. Secondary blood pressure outcomes, including daytime, nighttime, and central SBP, as well as diastolic blood pressure, will be analysed using the same modelling approach. Linear mixed-effects models inherently accommodate missing outcome data under a missing-at-random assumption; patterns of missingness will be explored descriptively.
Linear mixed models will be used for the primary analysis, utilising all available data. We will report the number of participants completing both intervention periods and reasons for dropout or missing data. Only ABPM sessions with great than or equal to 40 valid readings will be included in the primary analysis. Sessions with less than 40 readings will be reported descriptively but excluded from efficacy analysis. Withdrawn participants will not be replaced. A sensitivity analysis will compare results using complete cases only (participants with valid data from both periods). Linear mixed models will also be used for secondary outcomes including quality of life, perceived stress, diet quality and any other secondary outcomes collected.
Exploratory metabolomic and microbiome analyses will use differential feature testing to identify metabolites and taxa differentiating HAD+ from HAD. Spearman correlation coefficients will be used to examine associations between changes in metabolites, microbiome features, and blood pressure outcomes. These analyses are exploratory and hypothesis-generating, and results will be interpreted with consideration of the increased risk of false positives arising from multiple comparisons.
Data cleaning and analysis will be conducted using appropriate statistical software, including but not limited to STATA, SPSS, and R. A p < 0.05 will be considered statistically significant.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 322723 0
Government body
Name [1] 322723 0
NSW Ministry of Health Cardiovascular Research Capacity Program
Country [1] 322723 0
Australia
Primary sponsor type
University
Name
The University of Newcastle
Address
Country
Australia
Secondary sponsor category [1] 325645 0
None
Name [1] 325645 0
Address [1] 325645 0
Country [1] 325645 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321165 0
Hunter New England Human Research Ethics Committee
Ethics committee address [1] 321165 0
Ethics committee country [1] 321165 0
Australia
Date submitted for ethics approval [1] 321165 0
05/08/2025
Approval date [1] 321165 0
16/02/2026
Ethics approval number [1] 321165 0
2025/ETH02892

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 152878 0
Dr Erin Clarke
Address 152878 0
ATC Building Room 205, The University of Newcastle, University Drive, Callaghan, NSW 2308
Country 152878 0
Australia
Phone 152878 0
+61 2 4921 5646
Fax 152878 0
Email 152878 0
Contact person for public queries
Name 152879 0
Erin Clarke
Address 152879 0
ATC Building Room 205, The University of Newcastle, University Drive, Callaghan, NSW 2308
Country 152879 0
Australia
Phone 152879 0
+61 2 4921 5646
Fax 152879 0
Email 152879 0
Contact person for scientific queries
Name 152880 0
Erin Clarke
Address 152880 0
ATC Building Room 205, The University of Newcastle, University Drive, Callaghan, NSW 2308
Country 152880 0
Australia
Phone 152880 0
+61 2 4921 5646
Fax 152880 0
Email 152880 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: This is not apart of our current ethics approval.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.